Why NASDAQ:ALNY qualifies as a high growth stock.

Our stock screener has flagged ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) as a potential breakout candidate. This occurs when the stock shows signs of consolidation after a notable upward trend. While we can't predict the actual breakout, it's worth monitoring NASDAQ:ALNY for potential movement.

Deciphering the Technical Picture of NASDAQ:ALNY

ChartMill assigns a Technical Rating to every stock. This score, ranging from 0 to 10, is updated daily and is determined by evaluating multiple technical indicators and properties.

Overall ALNY gets a technical rating of 10 out of 10. This is due to a consistent performance in both the short and longer term time frames. Also compared to the overall market, ALNY is showing a nice and steady performance.

• Both the short term and long term trends are positive. This is a very positive sign.
• Looking at the yearly performance, ALNY did better than 91% of all other stocks.
• ALNY is part of the Biotechnology industry. There are 570 other stocks in this industry. ALNY outperforms 82% of them.
• ALNY is currently trading near its 52 week high, which is a good sign. The S&P500 Index however is also trading near new highs, which makes the performance in line with the market.
• In the last month ALNY has a been trading in the 264.15 - 286.02 range, which is quite wide. It is currently trading near the high of this range.

Our latest full technical report of ALNY contains the most current technical analsysis.

How does the Setup look for NASDAQ:ALNY

ChartMill incorporates a Setup Rating in its analysis, which measures the extent of consolidation in a stock over recent days and weeks. This rating, ranging from 0 to 10, is updated daily and takes into account multiple short-term technical indicators. The current setup rating for NASDAQ:ALNY is 7:

Besides having an excellent technical rating, ALNY also presents a decent setup pattern. We see reduced volatility while prices have been consolidating in the most recent period. There is a resistance zone just above the current price starting at 284.33. Right above this resistance zone may be a good entry point. Very recently a Pocket Pivot signal was observed. This is another positive sign.

Looking into the high growth metrics of ALNYLAM PHARMACEUTICALS INC

• ALNYLAM PHARMACEUTICALS INC has demonstrated consistent growth in its earnings per share (EPS) from one quarter to another (Q2Q), with a 94.12% increase. This indicates improving financial performance and the company's effective management of its operations.
• ALNYLAM PHARMACEUTICALS INC has experienced 107.0% q2q revenue growth, indicating a significant sales increase.
• With impressive 1-year revenue growth of 89.46%, ALNYLAM PHARMACEUTICALS INC showcases its ability to generate increased sales and revenue. This growth highlights the company's strong customer demand and its effective business strategies.
• Over the past 3 months, analysts have adjusted their EPS Estimate for ALNYLAM PHARMACEUTICALS INC with a 9.19% change. This highlights the evolving outlook on the company's EPS potential.
• In the most recent financial report, ALNYLAM PHARMACEUTICALS INC reported a 94.12% increase in quarterly earnings compared to the previous quarter. This notable growth indicates positive momentum in the company's financials, suggesting an upward trend
• accelerating EPS growth for ALNYLAM PHARMACEUTICALS INC: the current Q2Q growth of 94.12% exceeds the previous year Q2Q growth of 3.49%.
• With positive growth in its operating margin over the past year, ALNYLAM PHARMACEUTICALS INC showcases its ability to improve profitability through effective cost control and operational efficiency. This growth underscores the company's commitment to enhancing its financial performance.
• ALNYLAM PHARMACEUTICALS INC has shown positive growth in its free cash flow (FCF) over the past year, indicating improved cash generation and financial strength. This growth highlights the company's ability to effectively manage its cash flows and generate surplus funds.
• With a track record of beating EPS estimates in the last 4 quarters, ALNYLAM PHARMACEUTICALS INC showcases its consistent ability to deliver earnings surprises. This reflects the company's strong execution and its competitive position in the market.
• The Relative Strength (RS) of ALNYLAM PHARMACEUTICALS INC has consistently been strong, with a current 91.75 rating. This indicates the stock's ability to exhibit relative price outperformance and reflects its competitive strength. ALNYLAM PHARMACEUTICALS INC demonstrates promising potential for sustained price momentum.

Our High Growth Momentum Breakout screen will find you more ideas suited for high growth momentum breakouts.

Keep in mind

This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.